If you are reading this, you have probably already asked someone this question. Maybe a friend who has been through it. Maybe your partner, or your mother, or a sister who has loved you through every stage of this. Maybe you tried to squeeze it into the last minute of an oncology appointment. And the answers you have gotten, however kindly they were offered, have probably not been the answer you were looking for. Some version of be happy you're alive. A list of things to stop using, without explanation. A reassurance that you will worry about that later, when later never quite comes.

You deserved more than that. This is the piece you were looking for.

We have spent months reading the research on how cancer treatments interact with skincare ingredients — because nobody else has. What follows is an honest synthesis of what we found, what we did not find, and what you can do with that information today. It is not medical advice. It is the summary of the evidence that your care team has not had time to pull together for you, written by people who believe your skin, your reflection, and your sense of yourself matter even while your body is fighting to stay alive.

Cancer care in the United States is built around a team. Your oncologist leads it. A surgeon may have operated. A radiation oncologist may be running your treatment field. A pharmacist is checking for interactions. A nurse navigator is coordinating your visits. A social worker is helping you think about what comes next. A dietician may be helping you think about what to eat when nothing sounds good. For patients whose cancer or treatment burden warrants it, a palliative care specialist may be on the team, though access to that role is uneven even for the patients who most need it.

Cancer is too big for any one person, and the team model is the single most important advance in cancer care in the last generation. Your oncologist cares deeply about you and is doing extraordinary work to keep you alive.

But the care team, as it is currently structured, is missing a seat.

Your oncologist has limited data to reference on the specific question of how topical skincare ingredients interact with your treatment — because the synthesis largely does not exist in the medical literature in a form any clinician can pull in thirty seconds. She also has limited time. Her appointment with you is necessarily focused on the decisions that most affect your survival, and those decisions take most of her minutes. A workshop on face cream ingredients is not going to fit in, and you would not want it to — not if it came at the cost of the decisions that matter more.

Your oncology nurses are remarkable at what they do, and what they do is getting you through treatment cycles — managing symptoms, coordinating care, watching for complications that warrant escalation. A question about which moisturizer to use is outside the scope of their clinical practice. That is a boundary, not a failure.

The oncology pharmacist on your care team is the person best equipped, in theory, to think about ingredient interactions. She is also, for most patients, someone you will never directly meet. She works behind the scenes on your regimen. She is not sitting in front of you with a tube of face cream and an ingredient list to review.

Dermatologists are not routinely part of the cancer care team unless a specific skin complication arises. And if you had a dermatologist before your diagnosis — the kind of dermatologist you might have seen for cosmetic concerns, for the occasional peel, for guidance on aging skin — her clinical posture changes the moment she hears the word cancer. She is now watching for melanoma and other cancer-related concerns. That is the correct posture for her to take, and you want her watching for those things. But the aesthetic conversation you used to have with her has left the room. And the question you are asking here — how topical ingredients interact with oncologic therapies — is not something her training reliably covered in the first place, because that synthesis does not exist dependably in the dermatology literature either.

And the gap does not end at the clinical team. When a woman tries to find someone outside the hospital to help her look like herself again — or to help her process the fact that she cannot — she finds the consumer-facing ecosystem has the same hole in the middle of it.

Your therapist is talking to you about anxiety and lack of sleep, and probably recommending medication for both. Your sessions have turned to locus of control — letting go of what you cannot control, focusing your energy on what you can. When you try to explain how you are cleaning up the toxins in your life — throwing out the products with phthalates, switching your personal care one bottle at a time, reading ingredient labels for the first time in your life — she gently suggests you are overdoing it. That the effort itself is causing you anxiety. That you cannot control your environment, and the attempt is hurting more than it helps. Better to let it go.

Your plastic surgeon, if you have one, offers Botox. But after months of infusions, port accesses, blood draws, and biopsies, another needle — even a cosmetic one, even a small one — can feel like an impossible chasm to cross. The specialty that trades in needles is not equipped to meet a woman whose body has been pierced fifty times and who cannot stomach a fifty-first, even in pursuit of feeling more like herself.

Your hairdresser — the person who used to make you feel beautiful — now looks at you with pity, if you even still go to one. It may be years before you need to again. You see the look in the mirror as soon as you sit down in the chair. Whatever she says out loud, the look precedes it. And that look is a small daily reminder of the thing you are trying, for forty-five minutes, to get a break from.

Sephora, the store that used to be an uncomplicated pleasure, has become a minefield. You stand in an aisle and cannot evaluate whether the ingredients in a serum might interact with your treatment, whether a moisturizer's fragrance will flare your post-radiation skin, whether the anti-aging promise on a bottle is formulated in a way that is wise for your body right now. The salespeople mean well. When you ask what is clean, they point you toward the vegan products — as if the absence of animal ingredients were the same as the absence of endocrine disruptors. It is not. A vegan serum can be loaded with phthalates, synthetic fragrance, and the exact ingredients you are trying to avoid. The store does not have the vocabulary to answer your actual question, and the shortcut it offers in place of an answer is pointing in the wrong direction.

And the skincare brands that position themselves as science-backed — the ones you might have expected to meet you here — fail the cancer audience in three predictable ways. Some are priced out of reach, because premium positioning is part of their brand strategy. Some are sophisticated on ingredients but have not thought about cancer treatment as a use case, so their product guidance stops at sensitive skin without ever asking what caused the sensitivity. And some, most painfully, are happy to carry ingredients now understood to be endocrine disruptors — the same chemical class that the most serious research on environmental contributors to hormone-driven cancers has been pointing toward for decades. The brand that might have a defensible product for you may also be carrying, two shelves over, the ingredients that may have helped get you here in the first place.

This is the gap — inside the clinic and outside of it. And patients have been falling into it for decades.

The gap becomes most visible in a particular moment — not in a clinic, but at home. It happens in front of a bathroom mirror, or in the reflection of a car window on the way home from an appointment, or in a photograph someone took without asking. It is the moment you do not recognize yourself. And the moment you mention it to someone who loves you, the answer you get — gentle, well-meaning, kindly intended — is some version of be happy you're alive.

They mean it as comfort. And you are happy you are alive. You are grateful for every person on the team that got you here. None of that is the point. The point is that cancer treatment takes something from a woman beyond what the treatment is trying to take from the cancer. It takes, for a while, your ability to see yourself. And telling a woman to just be grateful for survival, when she is staring at a stranger in her own mirror, is not the answer she needs — even when it is offered by people who love her.

That is not a failure of your loved ones, and it is not a failure of oncology, and it is not a failure of the people and businesses who used to make you feel beautiful. Your oncologist's attention is correctly focused on keeping you alive. Your nurses are correctly focused on getting you through each treatment cycle. Your pharmacist is correctly focused on systemic interactions. Your friends and family are correctly trying to comfort you. The professionals and retailers outside the clinic are doing what their roles were built to do. None of them are failing you. None of them are equipped for this. The seat that is missing is the one for this particular question — the seat where chemistry and recovery and reflection all meet.

That is the seat Juventude is trying to occupy.

Before we get to the research, we have to talk about why the answer to this question is harder than it should be.

You will find plenty of blogs and beauty articles that will cheerfully hand you a "cancer-safe routine" — a list of five products, usually with affiliate links, presented as if they will work for everyone who is going through any kind of cancer treatment. Those articles are doing their readers a disservice. There is no single routine that is correct for every cancer patient, for the same reason there is no single chemotherapy regimen that is correct for every cancer patient. The details matter, and the details are personal.

Four dimensions shape what the right answer looks like for you.

• The first is the cancer itself. Hormone-receptor-positive breast cancers — which make up roughly two-thirds of all breast cancers — respond to estrogen in ways that matter for skincare. Certain botanical ingredients with weak estrogenic activity, which would be completely fine for a woman being treated for a non-hormone-driven cancer, warrant a closer look for a woman whose treatment plan depends on keeping estrogen signaling as low as possible. A woman being treated for colon cancer, lung cancer, or a hematologic malignancy does not have this particular concern. A woman being treated for ovarian cancer, endometrial cancer, or hormone-receptor-positive breast cancer may.
  
• The second is the treatment type. Chemotherapy, radiation, endocrine therapy (tamoxifen and aromatase inhibitors), surgery, and immunotherapy leave completely different signatures on the skin. Chemotherapy tends to compromise the skin barrier systemically — the whole body, everywhere — through rapid-cell-division toxicity and dehydration. Radiation affects a specific field of skin with a specific dose over a specific period. Endocrine therapy, over years, gradually reduces the collagen density, oil production, and hydration capacity that estrogen normally supports. Surgery leaves local changes in a specific area. Immunotherapy can produce immune-mediated skin reactions that look like nothing else. The ingredient choices that help one of these do very little for another, and in some cases, the ingredient that helps one makes another slightly worse.
• The third is the phase of treatment. There is skincare that is appropriate during active treatment, when the skin is most compromised and stress on it needs to be minimized. There is skincare that is appropriate in the early recovery period, when the skin is rebuilding its barrier and beginning to tolerate more but is not yet ready for the actives it used to accept. And there is skincare that is appropriate in long-term survivorship, which is a different question again — one that involves thinking about not just what your skin needs now but what the years of treatment have done to the baseline it is rebuilding from.
• The fourth is your own skin. You were a person with a particular skin type before your diagnosis — sensitive, dry, oily, combination, acne-prone, or some mix of those. Cancer treatment does not erase that baseline; it layers on top of it. A woman whose skin was dry and sensitive before chemo is going to have a different treatment-skin experience than a woman whose skin was oily and resilient. The right answer for you takes both your cancer-treatment context and your underlying skin type into account.

This is why you should be skeptical of any source that offers you one routine to rule them all. The honest answer is: it depends. What we can do — what nobody else has done in a synthesized, readable form — is walk you through what the research says about the specific interactions that matter, and help you and your care team make a better-informed decision about what works for your situation.

That is what this post is for. It is the overview. From here, dedicated follow-up posts in this series dive into the particular situations: retinol during chemotherapy, retinol after chemotherapy, retinol during and after endocrine therapy, and — because the research here is genuinely nuanced — the specific question of whether bakuchiol is the right retinol alternative for a woman on an aromatase inhibitor.

But first, the research.

The single most important distinction to understand, before we get into any specific ingredient, is the difference between oral and topical.

Nearly every cautious article you will find about "antioxidants and cancer treatment" is about oral antioxidants — the high-dose vitamin C and E supplements, the green tea extract capsules, the curcumin pills that cancer patients sometimes take during chemotherapy hoping either to reduce side effects or to help the treatment work better. 

There is a real, ongoing scientific debate about whether oral antioxidant supplementation interferes with certain chemotherapies. 

Some chemotherapy drugs — notably the anthracyclines (doxorubicin) and platinum compounds (cisplatin) — rely partly on generating reactive oxygen species to kill cancer cells, and there is a theoretical concern that high-dose antioxidants could blunt that mechanism. 

Other chemotherapy drugs work through different mechanisms entirely. Taxanes like paclitaxel and docetaxel, vinca alkaloids, and antimetabolites like methotrexate and fluorouracil do not rely on oxidative stress for their cytotoxicity, and the antioxidant concern largely does not apply to them. ¹

The evidence from randomized controlled trials on oral antioxidants is mixed but, taken together, does not show a consistent pattern of reduced chemotherapy efficacy. A systematic review of thirty-two trials found that one study reported significantly increased toxicity from concurrent use of antioxidants with chemotherapy, while eighteen studies found significantly lower toxicity in the antioxidant groups than in controls. ² 

Another review concluded that the interaction question is genuinely unresolved and depends on the specific antioxidant, the specific chemotherapy agent, the dose, and the clinical context. ³

This is the debate you will read about in most cancer-and-skincare articles. And it is almost entirely beside the point if what you are asking about is a facial moisturizer.

Topical skincare at normal formulation concentrations produces minimal systemic absorption. The active ingredients in a serum or a cream largely stay in the upper layers of the skin, where they are supposed to work. The concentrations that reach the bloodstream — if they reach it at all — are tiny fractions of what an oral supplement delivers. For the ingredient-level concerns discussed below, this topical-versus-oral distinction is the master key that unlocks most of the complexity. It is not a free pass; it is a reason for calibrated calm.

With that frame in place, here is what the research shows for the three main treatment categories.

There is no published clinical trial that has directly tested whether topical antioxidant skincare — a vitamin C serum, a green tea moisturizer, a niacinamide cream — affects the efficacy of chemotherapy. The question simply has not been studied in that form. What the research base does offer is two adjacent bodies of evidence that, taken together, suggest the theoretical concern is unlikely to be practically meaningful.

The first is the absorption literature. Standard skincare formulations are designed to work at or near the skin's surface. The stratum corneum is an effective barrier, and active ingredients in serums and creams generally remain in the epidermis. The kind of transdermal absorption that produces clinically meaningful blood levels requires specific engineering — nicotine and hormone patches, for example, use delivery systems that typical cosmetic products do not. A vitamin C serum or green tea extract in a moisturizer is not formulated to cross into the bloodstream, and the evidence suggests it largely does not.

The second is the oral antioxidant literature. Even at the much higher systemic concentrations achieved by oral supplements, the aggregate evidence from randomized trials does not show consistent interference with chemotherapy efficacy. One systematic review of 33 randomized trials including 2,446 patients found that 24 studies reported reduced toxicity with concurrent antioxidants, 9 showed no difference, and only one (vitamin A) showed increased toxicity. That is not a clean bill of health — individual antioxidant-and-regimen combinations may still warrant caution, and this is a genuinely unresolved area — but it argues against the idea that the theoretical interference is a reliable clinical phenomenon even at oral-supplement doses.

There is also positive evidence that topical skincare helps during chemotherapy. A multicenter randomized crossover study of 73 breast cancer patients on anthracycline, taxane, or alkylating-agent chemotherapy found that twice-daily topical niacinamide over six weeks improved quality-of-life measures related to skin symptoms.

Green tea, aloe vera, and chamomile have all been tested in clinical trials on women receiving radiation therapy, where applying them to the treatment area reduced skin burning, peeling, and pain. No one has run the same trials specifically on chemotherapy patients, but because radiation skin and chemo skin end up in a similar state — inflamed, compromised, struggling to repair — these same ingredients are reasonable to consider for chemo support.

The practical takeaway is not "avoid all topical antioxidants during chemo" but rather the barrier-first framework the rest of this post describes: minimal-ingredient formulas, low concentrations of actives, no fragrance, no essential oils, and a heavy emphasis on barrier support.

Pause retinol, pause AHAs and BHAs, pause anything labeled "exfoliating" or "brightening" or "resurfacing." Your skin cannot tolerate that kind of work right now, and the work is not worth the cost.

The research base for topical skincare during radiation is the strongest of the three treatment categories, for reasons that make sense once you see them. Radiation-induced skin toxicity — radiation dermatitis — is the most common and most disruptive side effect of radiation therapy, the damage is localized to a predictable field, and topical products are the obvious intervention. It is the one cancer treatment where skincare is not an afterthought but a core part of how patients and clinicians manage side effects. A significant body of work has evaluated topical agents for prevention and management, and several antioxidants have shown meaningful clinical benefit.

A phase I trial of topical epigallocatechin-3-gallate (EGCG), the primary polyphenol in green tea, showed preliminary evidence that it relieves radiation-induced dermatitis in breast cancer patients receiving adjuvant radiotherapy. ⁴ Topical vitamin C has been evaluated in a double-blind randomized trial for radiation dermatitis prevention. ⁵ Aloe vera has been studied in multiple randomized trials for prevention of grade 2 or higher acute radiation dermatitis. ⁶ Chamomile, calendula, and other plant-derived anti-inflammatories have a substantial preclinical and clinical literature behind them for radiation skin support. ⁷

The current standard of care for radiation dermatitis still includes topical corticosteroids, which have the strongest evidence for reducing severity. ⁸ But the point is this: for radiation, the research does not say "avoid topical antioxidants." It says, to a meaningful extent, the opposite.

One operational note that matters: most radiation protocols ask patients to arrive at each session with clean, bare skin at the treatment field. That does not mean you cannot use skincare during radiation. It means the timing gets structured — typically, the evening routine is the full routine, and the morning routine before a session is minimal or deferred until after. Your radiation oncology team will give you specific guidance for your field.

Endocrine therapy — tamoxifen, aromatase inhibitors like anastrozole, letrozole, and exemestane, and drugs like fulvestrant — is an entirely different conversation. These drugs work through the hormone receptor pathway, not through oxidative mechanisms. The antioxidant-interaction concern that occupies most of the chemotherapy literature does not apply here.

The concern that does apply here is phytoestrogens.

Aromatase inhibitors work by preventing the conversion of androgens to estrogen, driving systemic estrogen levels in postmenopausal women to very low levels. Tamoxifen works by blocking estrogen receptors on breast tissue. In both cases, the therapeutic goal is to deprive hormone-receptor-positive breast cancer cells of the estrogen signaling they need to grow. Any substance that mimics estrogen, even weakly, has the theoretical potential to interfere with that goal.

Oral phytoestrogen supplementation during endocrine therapy is generally cautioned against. An in vitro study on menopausal supplements containing phytoestrogens found that they induced estrogen-receptor-dependent proliferation of breast cancer cells and overcame the effect of both letrozole and tamoxifen in a breast cancer cell model, with the authors concluding that menopausal phytoestrogen supplement intake during breast cancer treatment should be avoided. ⁹

The translation of this caution to topical skincare is not automatic. Topical application of a botanical is not the same as oral supplementation of the same compound. Systemic absorption from a face cream is a fraction of what an oral capsule delivers. But the direction of concern is real enough that specific topical ingredients with documented estrogenic activity warrant a closer look for women on endocrine therapy for hormone-receptor-positive breast cancer.

Two ingredients in particular are worth discussing.

Green tea and EGCG: a favorable picture. Despite showing weak phytoestrogenic activity in some assays, topical EGCG appears beneficial rather than concerning in the cancer context. A systematic review of green tea catechin interactions with breast cancer endocrine treatment reported experimental evidence of a synergistic interaction of green tea catechins with tamoxifen or raloxifene, and no evidence of an interaction of green tea catechins with aromatase inhibitors or fulvestrant. ¹⁰ Memorial Sloan Kettering Cancer Center's integrative medicine resource notes the radiation dermatitis data for topical EGCG and reports that green tea consumption has been associated with reduced breast cancer recurrence. ¹¹ For most women on endocrine therapy, topical green tea is a defensible ingredient, not one to avoid.

Bakuchiol: genuinely nuanced.

Bakuchiol is a plant compound extracted from the babchi plant (Psoralea corylifolia), used in traditional Ayurvedic medicine for centuries and adopted by modern skincare as a gentler alternative to retinol. It delivers similar anti-aging benefits — improved texture, reduced fine lines — without the irritation, peeling, and sun sensitivity retinol typically causes. Many clean-beauty brands have made it their hero ingredient, and Juventude uses it in our Age-Well Sensitive routine for this reason.

For most women, bakuchiol is a straightforward win. For women with hormone-receptor-positive breast cancer — especially those on aromatase inhibitors or tamoxifen — the picture is more complicated, because bakuchiol has been characterized as a phytoestrogen. That word deserves explanation.

A phytoestrogen is a plant compound that can weakly mimic the hormone estrogen in the body. The way to picture it: estrogen receptors on a cell work like locks, and estrogen itself is the key that opens them and tells the cell what to do. A phytoestrogen is a different, plant-derived key that can fit into the same lock — not as well as real estrogen, but well enough to turn it partway. The best-known phytoestrogen is genistein, from soy.

The soy comparison is worth pausing on, because it is a reminder that the science here has moved — and is still moving. For decades, soy was feared as a breast cancer risk precisely because of its phytoestrogen content. Early cell-culture and rodent studies showed genistein stimulating estrogen-receptor-positive breast cancer cells to grow, and a generation of women, especially survivors, were told to avoid it.

The current scientific consensus is very different. Large human studies — including a prospective cohort of over 300,000 Chinese women — have shown that dietary soy is associated with reduced breast cancer risk, ¹² and post-diagnosis soy intake has been linked to lower recurrence and better survival in women with breast cancer. ¹³ The American Cancer Society, ¹⁴ the American Institute for Cancer Research, ¹⁵ and the European Food Safety Authority now all agree that moderate soy food consumption is safe for breast cancer survivors and may be actively protective.

Two things explain why the early studies turned out to be misleading. First, rodents metabolize isoflavones very differently than humans — the blood levels seen in rodent experiments do not occur in humans eating soy food. Second, not all estrogen receptors do the same thing. There are different types of estrogen receptors in the body, and activating them produces different effects — some types promote cell growth, others oppose it. Isoflavones preferentially bind the type that opposes cancer growth, rather than the type that drives it. What looked like generic "estrogenic activity" in a lab dish turns out, in an intact human body, to be something more selective — and in the case of dietary soy, something that the evidence now suggests is protective.

One important caveat remains: this update applies to soy food. Concentrated soy supplements, which deliver far higher isoflavone doses than diet alone, are still not recommended by the major cancer organizations, and the research there remains more uncertain.

All of which matters for bakuchiol in three specific ways.

First, the soy history is a warning against overinterpreting lab-dish findings. "Showed phytoestrogen activity in a cell culture" turned out not to reliably predict what happens in a human body eating soy. The bakuchiol studies discussed below are also lab-dish findings, and they deserve the same skepticism the soy studies did.

Second, the soy framework lets us ask a better question about bakuchiol. Is topical bakuchiol in a face cream more like soy food — small amounts, metabolically different from dish conditions, likely protective or neutral? Or is it more like a concentrated soy supplement — a purified compound, structurally closer to what gets tested in a dish, where more caution applies? Bakuchiol in skincare is a purified compound, which structurally looks more like a supplement than a food — but it is also delivered topically, in quantities likely smaller than either. That question has not been directly studied in humans.

Third, bakuchiol's receptor preferences are less understood than soy's. We do not yet know whether bakuchiol preferentially binds the protective or the growth-promoting type of estrogen receptor. One of the cell studies below hints toward the growth-promoting type, but the picture is incomplete.

With all of that framework in place, here is what the two most directly relevant studies on bakuchiol actually show.

The first study¹⁶ took compounds extracted from the babchi plant and tested how strongly each one fit into estrogen receptors in a lab dish. Bakuchiol fit most tightly of all the compounds tested. The researchers then measured whether that fit translated into actually causing cells to multiply — the way real estrogen would — and at the same concentration, bakuchiol's activity was similar to that of genistein, the soy phytoestrogen. In plain language: in a lab dish, at the doses tested, bakuchiol behaves the way soy's phytoestrogen does.

The second study¹⁷ went further, testing bakuchiol directly on breast cancer cells in a lab dish — specifically on a well-studied line of estrogen-receptor-positive breast cancer cells, the same kind of cancer most often treated with aromatase inhibitors. The findings split in two opposite directions, depending on the dose:

• At low concentrations, bakuchiol caused the breast cancer cells to grow more, as if it were acting like estrogen and fueling them. The researchers confirmed the mechanism was estrogen-driven by blocking it with an anti-estrogen drug and watching the growth effect disappear.
• At higher concentrations, bakuchiol did the opposite: it inhibited breast cancer cell growth.

This pattern — a compound doing one thing at low doses and the opposite at high doses — is called a biphasic dose response and is not unusual among phytoestrogens. The practical problem is that nobody has measured which dose range actually reaches breast tissue when a woman uses a face cream containing bakuchiol. It could be negligibly low. It could be in the low range that the second study associated with cancer cell growth. Or it could be in the higher range that inhibited growth. The study that would answer this question has not been done.

What to make of all of this.

The same qualifiers that reframed the soy story apply here, possibly more forcefully. Every finding discussed above was produced in cell culture or animal models, not in women using a formulated face cream. Topical application delivers far less of an ingredient into the bloodstream and other tissues than oral supplementation does. There is no published evidence that topical bakuchiol in formulated skincare has produced clinically meaningful estrogenic effects in humans.

But unlike soy, bakuchiol has not yet accumulated the large human-population studies that eventually reassured the cancer community about dietary soy. And the signal from the cell and animal work is real enough that we believe women on aromatase inhibitors for hormone-receptor-positive breast cancer deserve to know about it, and deserve to make an informed decision in conversation with their oncology team. We have written a dedicated post on this specific question — the laboratory phytoestrogen findings, the topical-versus-oral distinction, the honest case for and against, and the lowest-risk alternative products if the uncertainty leaves you wanting to avoid bakuchiol during AI treatment.

The specifics of your situation shape the specifics of your routine. But seven principles apply to almost everyone going through cancer treatment, regardless of cancer type, treatment type, or skin type. If you do nothing else — if you are reading this a day before your first infusion and you need a starting point — these seven principles are the starting point.

1. Your emotional response to your reflection is real data about what your skin needs. This is the first principle and the most important one. The medical framing of skincare during cancer treatment tends to stop at barrier function, infection risk, and transepidermal water loss. Those things are real and they matter. But they are not the whole picture. Feeling unrecognizable in your own mirror is not a vanity problem — it is a mental health problem, and it is a recovery problem, because your capacity to feel like yourself is part of your capacity to move through and beyond treatment. The clinical principles below exist in service of that larger principle, not in place of it.

2. Simpler is safer. Fewer ingredients, lower concentrations, no fragrance, no essential oils, no harsh actives. Compromised skin absorbs more and tolerates less than healthy skin. Every ingredient in your routine should be there because it is earning its place.

3. Barrier-first, always. The skin barrier is what is most compromised during treatment, and it is what most needs support. Ceramides, panthenol, squalane, hyaluronic acid, and carefully chosen plant oils (jojoba, tamanu) are the workhorses. Gentle surfactants matter in cleansers. The goal is to reinforce, not to strip.

4. Hydration is the foundation, not a step. Treatment-era skin loses water faster than healthy skin and recovers slower. Layered hydration — a humectant serum under an emollient cream — does more than a single heavy moisturizer. Apply to slightly damp skin for better performance.

5. SPF is non-negotiable. This applies across every treatment type. Chemotherapy often causes photosensitivity. Radiation creates a field that will be sun-sensitive for months or years. Some endocrine therapies thin the skin and reduce its natural photoprotection. Daily broad-spectrum SPF 30 or higher is not optional, and mineral formulations (zinc oxide, titanium dioxide) are generally the better choice for sensitive and post-treatment skin.

6. Pause retinol during active treatment. Retinol's mechanism — increased cell turnover, temporary barrier disruption, photosensitivity — is not compatible with what your skin is doing during chemotherapy or radiation. Pause it at diagnosis or treatment start. Do not taper. Do not alternate nights. Just stop. We go deeper on this in the individual posts that follow, including on when and how to reintroduce it after treatment.

7. Minimal-ingredient formulas beat complex ones on compromised skin. A serum with four well-chosen ingredients will usually do more for treatment-era skin than a serum with thirty. This is one of the few cases in skincare where less actually is more, and it is the single easiest rule to follow when you are standing in a pharmacy aisle exhausted after an appointment and trying to figure out what to buy.